// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1671 Abstracts

SINGLE INSTITUTION EXPERIENCE WITH S-1 (TEYSUNO) IN DANISH PATIENTS WITH GASTRO-INTESTINAL CANCER

Per Pfeiffer - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hand foot syndrome

Capecitabine

HOSPITAL BASED OBSERVATIONAL STUDY ON THE TOLERABILITY, AND EFFICACY OF TWO GEMCITABINE OXALIPLATIN REGIMENS

Mudhasir Ahmad - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2013

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Gemcitabine

WILL CIRCULATING BIOMARKERS HELP TO DELIVER PRECISION MEDICINE?

D. Olmos - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Prostate cancer

Enzalutamide

CIRCULATING TUMOUR CELLS: ISOLATION, ENRICHMENT AND CLINICAL VALUE IN BREAST CANCER

M. Ignatiadis - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

TTD CONTRIBUTION TO THE PRECISION ONCOLOGY

E. Aranda Aguilar - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

CIRCULATING TUMOR CELL (CTC) COUNT AND EXPRESSION OF PERK AND PAKT IN CTCS AS BIOMARKERS FOR SORAFENIB EFFICACY IN ADVANCED HEPATOCELLULAR CARCINOMA

J. LI - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

MONITORING CIRCULATING TUMOR CELLS (CTC) IN LUNG CANCER: PRELIMINARY RESULTS

M.E. Olmedo - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

CHARACTERIZATION AND DETECTION OF CIRCULATING TUMOR CELLS IN MULTIPLE MYELOMA PATIENTS

F.Y. Lee - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

CIRCULATING TUMOR CELLS AS BIOMARKERS DURING NEOADJUVANT CHEMOTHERAPY IN BLADDER CANCER

A.S. Alva - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cisplatin

CHARACTERISTICS OF DE NOVO RESISTANCE TO ANDROGEN TARGETING THERAPEUTICS (AR TX) THROUGH CIRCULATING TUMOR CELLS (CTCS) ANALYSIS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS

R.M. Bambury - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Androgen Tear

CHARACTERIZATION OF CIRCULATING TUMOR CELLS (CTCS) OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS IN FIRST, SECOND & THIRD LINE SYSTEMIC THERAPIES

H.I. Scher - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

BIOMARKER ANALYSES OF A PHASE I/II STUDY OF NANOPARTICLE ALBUMIN-BOUND PACLITAXEL PLUS CISPLATIN IN THE TREATMENT OF ADVANCED NASOPHARYNGEAL CARCINOMAS

W. Liang - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Nasopharyngeal carcinoma

Protein-bound paclitaxel

PREDICTORS OF HYPERTENSION IN IBCSG 18-98 / BIG 1-98: ADJUVANT THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, EARLY BREAST CANCER

M. Rabaglio-Poretti - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hypercholesterolemia, Familial, 1

N/A

CIRCULATING TUMOR CELL COUNT AT BASELINE IS AN INDEPENDENT PROGNOSTIC FACTOR FROM PATHOLOGICAL COMPLETE RESPONSE AMONG PATIENTS TREATED FOR PRIMARY INFLAMMATORY HER2-POSITIVE BREAST CANCER: SURVIVAL RESULTS OF THE BEVERLY-2 STUDY

J. Pierga - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

CLINICAL SIGNIFICANCE AND THE DETECTION OF CIRCULATING TUMOR CELLS IN PERIPHERAL BLOOD OF PATIENTS WITH BREAST CANCER

J. Liu - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

PIK3CA MUTATIONS AND LOSS OF PTEN EXPRESSION IN CIRCULATING TUMOR CELLS (CTCS) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC)

R. Lozano Mejorada - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

DETECTION OF HER2 STATUS OF CIRCULATING TUMOR CELLS IN PATIENTS WITH METASTATIC BREAST CANCER

X.L. Dong - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

CIRCULATING TUMOR CELLS ANALYSED BY SCANNING FLUORESCENCE MICROSCOPY IN THE XENA TRIAL

T. Hillig - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Vinorelbine

A PHASE IB STUDY OF EVEROLIMUS, 5-FLUOROURACIL (5-FU) AND PELVIC RADIOTHERAPY (RT) AS NEO-ADJUVANT TREATMENT FOR LOCALLY ADVANCED RECTAL CANCER (LARC)

F. Bertolini - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Adrucil injection

PHASE IB TRIAL TO EVALUATE CAPECITABINE (C), ERLOTINIB (E), AND BEVACIZUMAB (B) IN PATIENTS (PTS) WITH UNRESECTABLE AND/OR METASTATIC PANCREATIC CANCER (UMPC) PRELIMINARY RESULTS OF THE REBECA TRIAL INCLUDING PHARMACOKINETICS (PK) AND CIRCULATING TUMOR CELLS (CTCS)

C. Dittrich - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

Capecitabine

Copyright © 2026. QuantiNova All rights reserved